Takeda Pharmaceutical Company (4502) investor relations material

Leadership transition and organizational changes

• Incoming CEO Julie Kim brings over 30 years of life sciences experience, including leading Takeda’s plasma business and U.S. operations.

• Kim has already implemented a new executive team and flattened the organization to improve efficiency and decision-making.

• New talent, including Rhonda Pacheco, has been brought in to strengthen leadership, especially for major product launches.

• Three new board members are joining, bringing expertise in R&D, U.S. payer landscape, and financial oversight.

Product launches and pipeline strategy

• Three major launches are planned: oveporexton for Narcolepsy Type 1 and rusfertide for polycythemia vera this fiscal year, and zasocitinib for psoriasis in the first half of next fiscal year.

• Oveporexton is expected to see rapid uptake due to its transformative potential, while rusfertide will have steadier growth.

• Zasocitinib offers rapid onset, no food restrictions, and durable efficacy in a competitive market.

• The orexin portfolio includes follow-up compounds TAK-360 and TAK-495, targeting broader sleep disorder indications.

• Oncology pipeline features TAK-928 and TAK-921, with TAK-928 positioned as a potential next-generation immuno-oncology blockbuster.

Financial outlook and transformation plan

• Revenue is expected to decline slightly this year due to loss of exclusivity for Vyvanse and TRINTELLIX, but growth is projected to resume next year.

• The company is executing a transformation plan targeting JPY 100 billion in savings this year, rising to JPY 200 billion annually.

• Horizon One (next 2–3 years) focuses on executing launches, pipeline delivery, core brand resilience, and organizational transformation.

• Horizon Two will see the impact of new launches and additional late-stage assets, with a goal of achieving low to mid 30% core operating profit margin and reducing leverage to 2x.

• Capital allocation will prioritize selective business development and shareholder returns as leverage improves.